In this podcast, Commercializing Living Therapies with CCRM, Ken Harris, OmniaBio, and Christopher P. Boone, PhD, Oracle, explore how artificial intelligence (AI) and robotics are shaping the biomanufacturing facility of the future. Our guests discuss the technologies behind automation, including robotics, AI and machine learning, and how they play a role in development and manufacturing facilities for cell and gene therapies. They also cover the impact of these technologies on resolving challenges, like production bottlenecks, cost management and consistent quality control. As well, they illuminate how these technologies can affect both patients and clinicians.
The episode concludes by highlighting some key considerations, including the importance of implementing change management activities as biomanufacturers bring both their organizations and customers along as their facilities evolve, as well as the need to upskill and reskill talent, and to collaborate with experts, to support scalability.
Guests:
- Ken Harris, Chief Strategy Officer and Head of AI at OmniaBio
- Christopher P. Boone, PhD, Group Vice President, Research Services, Health & Life Sciences at Oracle
